OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
66 hedge funds and large institutions have $61M invested in OncoMed Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 13 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
4% less funds holding
Funds holding: 69 → 66 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
27% less capital invested
Capital invested by funds: $83.9M → $61M (-$22.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$465K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$245K |
| 3 |
BC
Birchview Capital
Burlington,
Vermont
|
+$193K |
| 4 |
SIM
Spark Investment Management
New York
|
+$163K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$2.01M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.81M |
| 3 |
Millennium Management
New York
|
-$856K |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$570K |
| 5 |
PP
PDT Partners
New York
|
-$242K |
OMED Hedge Fund Activity: Q1 2018 in Review
66 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q1 2018, worth a combined $61M — down 27% from $83.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of OMED and 10 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 18 added.
The largest buyer was Renaissance Technologies, adding an estimated $465K. The largest seller was Adams Street Partners, exiting entirely with an estimated $2.01M sold.
- 66 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q1 2018, down from 69 in Q4 2017.
- Funds reported $61M of OncoMed Pharmaceuticals, Inc. stock for Q1 2018, down 27% quarter-over-quarter.
- 10 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q1 2018 and 13 closed out, a net change of -3 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q1 2018 was Renaissance Technologies, an estimated $465K added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q1 2018 was Adams Street Partners, an estimated $2.01M sold.
Based on aggregated 13F filings for Q1 2018.